Dipeptidyl peptidase-4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase -4抑制剂：多靶点药物，不仅仅是降糖药)

DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

(2012) Matteo Monami et al.   ADVANCES IN THERAPY

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition

(2012) Swenja Kröller-Schön et al.   CARDIOVASCULAR RESEARCH

Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice

(2012) L. Chen et al.   CURRENT MOLECULAR MEDICINE

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition

(2012) M. R. Rizzo et al.   DIABETES CARE

Sitagliptin-Associated Angioedema

(2012) A. R. Gosmanov et al.   DIABETES CARE

Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells

(2012) J. Liang et al.   DIABETES OBESITY & METABOLISM

Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice

(2012) F. Briand et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

(2012) M. Monami et al.   DIABETES OBESITY & METABOLISM

The Effect of Sitagliptin Versus Glibenclamide on Arterial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients

(2012) Shlomit Koren et al.   Diabetes Technology & Therapeutics

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

(2012) Limei Liu et al.   HYPERTENSION

Sitagliptin (DPP-4 Inhibitor)-induced Rheumatoid Arthritis in Type 2 Diabetes Mellitus: A Case Report

(2012) Kazuki Yokota et al.   INTERNAL MEDICINE

Sitagliptin Exerts an Antinflammatory Action

(2012) Antoine Makdissi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice

(2012) Junichi Matsubara et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The impact of blood coagulability on atherosclerosis and cardiovascular disease

(2012) R. LOEFFEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn’s disease

(2012) Meike Körner et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression

(2012) Joana Rosmaninho-Salgado et al.   PEPTIDES

Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers

(2012) Ashish Kumar Gupta et al.   PLATELETS

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats

(2012) Soo Lim et al.   PLoS One

Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor and a Proton Pump Inhibitor Induces β-Cell Neogenesis from Adult Human Pancreatic Duct Cells Implanted in Immunodeficient Mice

(2011) Wilma L. Suarez-Pinzon et al.   CELL TRANSPLANTATION

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

(2011) Zubair Shah et al.   CIRCULATION

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice

(2011) J. Shirakawa et al.   DIABETES

Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase

(2011) M. J. Willemen et al.   DIABETES CARE

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

(2011) A. J. Tremblay et al.   DIABETES OBESITY & METABOLISM

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial

(2011) S. L. Ellis et al.   DIABETIC MEDICINE

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

(2011) Nelson Gomez et al.   EUROPEAN JOURNAL OF HEART FAILURE

A Case of Drug-induced Hepatic Injury Associated with Sitagliptin

(2011) Megumi Toyoda-Akui et al.   INTERNAL MEDICINE

Altered Proportions of Naïve, Central Memory and Terminally Differentiated Central Memory Subsets among CD4+ and CD8+ T Cells Expressing CD26 in Patients with Type 1 Diabetes

(2011) Elena Matteucci et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation – The Hoorn Study

(2011) Hanneke J.B.H. Beijers et al.   THROMBOSIS RESEARCH

Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes

(2011) Susumu Ogawa et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

(2010) A. D. Dobrian et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts

(2010) Caroline Ospelt et al.   ARTHRITIS AND RHEUMATISM

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

(2010) Philip A. Read et al.   Circulation-Cardiovascular Imaging

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Severe leucopenia associated with Sitagliptin use

(2010) Dario Pitocco et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]

(2010) Sachiko Hattori   ENDOCRINE JOURNAL

Reversal of New-Onset Diabetes through Modulating Inflammation and Stimulating β-Cell Replication in Nonobese Diabetic Mice by a Dipeptidyl Peptidase IV Inhibitor

(2010) Lei Tian et al.   ENDOCRINOLOGY

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

(2010) Annis Marney et al.   HYPERTENSION

Sitagliptin-induced hemolysis

(2010) Ragini Bekur et al.   INDIAN JOURNAL OF PHARMACOLOGY

Dipeptidyl peptidase expression during experimental colitis in mice

(2010) Roger Yazbeck et al.   INFLAMMATORY BOWEL DISEASES

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

(2010) Bruna PM Pacheco et al.   JOURNAL OF HYPERTENSION

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

(2010) Liliana Ferreira et al.   MEDIATORS OF INFLAMMATION

Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice

(2009) W. L. Suarez-Pinzon et al.   DIABETOLOGIA

Angiotensin-Converting Enzyme and Dipeptidyl Peptidase IV Inhibitors

(2009) Eric Grouzmann et al.   HYPERTENSION

Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema

(2009) Nancy J. Brown et al.   HYPERTENSION

The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9–36)a in an isolated rat heart

(2009) Alvilde Ossum et al.   PHARMACOLOGICAL RESEARCH

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently

(2008) C. Klemann et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation

(2008) S.-J. Kim et al.   DIABETES

Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension

(2008) Edwin K. Jackson et al.   HYPERTENSION

Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients

(2008) Michael Boschmann et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor

(2007) Mario Gonzalez-Gronow   Frontiers in Bioscience-Landmark